Systems Approaches in Osteoarthritis: Identifying Routes to Novel Diagnostic and Therapeutic Strategies by Mueller, Alan J et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved 
 
1 
Perspectives 
Systems approaches in osteoarthritis: Identifying routes to novel 
diagnostic and therapeutic strategies† 
Running title: Systems approaches in osteoarthritis  
Alan J. Mueller1, , Mandy J. Peffers1,3, Carole J. Proctor2,3, Peter D. Clegg1,3*  
1. Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, 
Faculty of Health & Life Sciences, University of Liverpool, William Henry Duncan 
Building, 6 West Derby Street, Liverpool, L7 8TX, United Kingdom 
2. Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle 
upon Tyne, NE2 4HH, United Kingdom 
3. The MRC-Arthritis Research UK Centre for Integrated Research into 
Musculoskeletal Ageing (CIMA) 
*Corresponding author: Prof. Peter D. Clegg (pclegg@liverpool.ac.uk) 
Author contribution statement 
AJM, MJP, CP, and PDC all revised and contributed to the article.  All authors 
approved the final submitted manuscript.   
 
 
 
 
 
†This article has been accepted for publication and undergone full peer review but has 
not been through the copyediting, typesetting, pagination and proofreading process, 
which may lead to differences between this version and the Version of Record. Please 
cite this article as doi: [10.1002/jor.23563] 
 
Additional Supporting Information may be found in the online version of this 
article. 
 
Received 13 December 2016; Revised 17 February 2017; Accepted 6 March 
2017 
Journal of Orthopaedic Research 
This article is protected by copyright. All rights reserved 
DOI 10.1002/jor.23563 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved 
 
2 
Abstract 
Systems orientated research offers the possibility of identifying novel therapeutic 
targets and relevant diagnostic markers for complex diseases such as osteoarthritis. This 
review demonstrates that the osteoarthritis research community has been slow to 
incorporate systems orientated approaches into research studies, although a number of 
key studies reveal novel insights into the regulatory mechanisms that contribute both to 
joint tissue homeostasis and its dysfunction.  The review introduces both top-down and 
bottom-up approaches employed in the study of osteoarthritis.  A holistic and multiscale 
approach, where clinical measurements may predict dysregulation and progression of 
joint degeneration, should be a key objective in future research.  The review concludes 
with suggestions for further research and emerging trends not least of which is the 
coupled development of diagnostic tests and therapeutics as part of a concerted effort 
by the osteoarthritis research community to meet clinical needs. This article is protected 
by copyright. All rights reserved 
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Introduction  
 
Osteoarthritis (OA) has been recognised in the earliest forms of man, and throughout 
animal species, located wherever there is a diarthrodial articular surface.  Yet, as we 
approach 275 years since William Hunter’s description of ulcerated cartilage as ‘a 
very troublesome disease’ [1] the therapeutic strategies available range from benign 
neglect to whole joint replacement.  OA cannot be considered a single disease with a 
linear narrative describing its pathogenesis, rather it is a heterogenous condition of 
multiple causation with a degenerate, non-functional joint the common end-point [2]. 
Subject to repetitive cycles of loading over many years the joint represents the 
functional product of integrated multisystem, multiphysics, and multiscale units [3].  
The objective of this review is to consider afresh whether the osteoarthritis research 
community has tackled the need for novel OA therapeutics and diagnostics by 
applying recent developments in systems biology.  Suggestions are made for areas of 
research that require further development and methods, which have shown utility in 
other disciplines, as described.  We consider mechanotransduction in osteoarthritis as 
a systems orientated case-study, but there are no OA studies that demonstrate the 
iterative and cyclical process of testing, validation, and refinement consistent with a 
systems biology approach.  Additionally, we wish to consider why, given the decades 
of research and prevalence of OA [4], that there are still no disease modifying 
therapeutics or prognostic markers and how progress should proceed with respect to 
trends and regulatory frameworks.  Not all tissues contributing to OA are well-
represented in systems orientated studies and where possible pertinent examples are 
provided.   
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Biology as a system 
A biological system is a set of elements (for example genes, proteins, and 
metabolites) with multiple and diverse functions; these elements interact in a specific 
and non-linear manner to produce coherent behaviours over time.  Evolution has 
defined specialised interactions creating functional systems and sub-systems at the 
cell, tissue, organ, organismal, and population/ecological levels [5].  Critically, the 
functional nature of the system is neither a characteristic of single elements, or only of 
the interactions of these elements; rather, behaviour arises from a combination of 
these characteristics.  The Human Genome Project demonstrated that biology is an 
information science.  Information is hierarchical [6] and this structure is replicated in 
biological systems (DNA-mRNA-proteins).  Therefore, complexities inherent to 
biological systems must be addressed using computational solutions as traditional 
reductionist strategies, intuition, and cognitive capacity alone will not be sufficient to 
develop a predictive understanding of biological systems and their derangements [7].  
It is the primary purpose of a systems biology approach to harvest high-quality data in 
a systematic and comprehensive manner from all levels of the biological hierarchy 
and integrate this data with the intention of developing predictive models of the 
system.  With this objective in mind it is necessary to consider that not only is the 
quality of the data variable, but often incomplete and biased.  Genes of unknown 
function, or unknown interacting partners, are often ignored and emphasis is often 
placed on those most studied.  Functional annotations relating to musculoskeletal 
disease, especially OA, are poor and result in spurious descriptors.  These important 
issues have been realised [8] and methods to improve annotations are being developed 
[9].   
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Systems Biology: a paradigm shift in science  
Fundamental definitions and frameworks for a systems approach have been well-
described [6, 10-13] and are covered briefly with respect to OA research, Figure 1.  
In this review we consider ‘systems orientated’ [7] approaches to OA; frequently OA 
studies do not fulfill the requirements of a holistic systems biology approach.  
Systems orientated studies may begin without a clear hypothesis and are often 
agnostic to pre-existing knowledge of molecular biology.  This initial stage 
comprehensively catalogues the elements present in the system under investigation 
and consists of single or multi-omics surveys (transcriptome, proteome, epigenome, 
metabolome).  Time is an important component of this approach and dynamic 
observations should be made.  Much of the contemporary OA literature achieved the 
first stage, however, a systems biology approach must proceed with an iterative series 
of systematic perturbations and quantifications to measure elements from all the 
distinct levels of a biological system. In an attempt to recapitulate the behaviour of the 
system all the quantitative data must be integrated into a network model. This 
mathematical model is reconciled with observed responses then a new hypothesis is 
formulated and tested experimentally.  It is not the purpose of this review to assess the 
extent to which an OA study conforms to the ideals of a systems biology approach 
rather recognise the contribution each study makes towards such an approach, and 
define the gaps in our understanding of OA pathogenesis.  In time this should aid the 
design of future studies with view to ultimately establishing OA diagnostic tests and 
therapeutics.   
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Complexity in osteoarthritis 
OA is the most prevalent chronic joint disease and the most common co-morbidity of 
the ageing population.  Incidence increases with age and is also associated with other 
predisposing factors such as obesity and joint trauma [14].  The biomechanical failure 
of articular cartilage, together with changes in other joint tissues, demonstrates that 
OA is a whole joint disease as early changes are also evident in subchondral bone [15] 
and synovium [16].  OA should be considered a complex disease; the disease 
phenotype is a consequence of the interplay between heterogeneous and multiple 
genomic variants, dysfunctional regulatory systems, and environmental contributions 
with spatiotemporal distributions [17-19]. The identification of genes responsible for 
common Mendelian traits, by linkage and linkage disequilibrium analysis [17], has 
not been possible for OA; defining causative mutations from phenotypic associations 
has demonstrated few candidate risk loci.  Whilst insidious degeneration results in a 
common end-point, a non-functional articulation, the initiating causes or mechanisms 
are often unclear.  For the homeostasis or health of the joint stability of the system 
arises as a function of the integrated behaviour of the biological, mechanical, and 
structural elements of the system [20].  In Chu, et al [21] an apt analogy is made 
between the probability of developing OA and the alignment of biological, 
mechanical, and structural factors as a slot/fruit machine. With each of these factors, 
and other associated risks, there is a probability of incitement of pre-osteoarthritis as 
the homeostatic mechanism becomes dysregulated.  The early consideration of the 
abnormal characteristics of these components, and inclusion of known prior risk 
factors promoting a propensity to OA, would be useful in determining at risk groups. 
When considered in this way it is clear that the historical focus on the end-stage OA 
phenotype has distracted from recognising the relationship between all factors.  
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Despite understanding that the inciting factors are likely to be heterogeneous we still 
recognise similar disease phenotypes; this suggests that at least some common 
elements of the system are likely to be dysregulated at some stage [18].  
Fundamentally, those elements that preserve the homeostatic system are still poorly 
understood.  Using systems biology approaches it becomes possible to understand 
how these elements interact or infer the missing nodes.  Through understanding how 
the homeostatic system responds to perturbations, rational approaches to diagnostic 
tests and therapeutic development can be made.  When considering publications since 
the turn of the century, explicitly considering systems biology and OA, only a small 
increase in investigations in this field in recent years is evident, Figure 2.      
 
Systems orientated studies exploring OA  
In the interest of brevity notable systems orientated studies in OA will be considered 
generally as ‘top-down’ (‘omics integration, network-based, metabolic and image-
based studies) and ‘bottom-up’ (dynamical models and molecular and pathway 
analyses).  The studies are chosen as examples of the research objectives associated 
with a systems orientated approach to OA.   
 
In vitro models - Routes to regeneration and cell therapies  
Tissue engineering and regenerative therapies are a major focus of attempts to modify 
the progression of OA [22].  In general, much of the in vitro basic OA research, in 
particular for chondrocytes, is still undertaken using monolayer or well-established 
three-dimensional culture models.  Two transcriptomic studies have considered the 
underlying mechanisms associated with differentiation transitions for in vitro 
chondrocytes using systems approaches.  By understanding the regulatory 
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mechanisms of de- and re-differentiation transitions chondrocytes may be 
manipulated in tissue-engineering and regenerative medicine.  Work from our group 
defined mechanistic networks associated with phenotypic transitions in two- and 
three-dimensional culture systems relative to native cartilage [23].  Revealing gene 
expression in chondrocytes at the single cell level Cote and colleagues [24] found 
considerable cell-to-cell heterogeneity in gene expression both in chondrocytes and 
mesenchymal stem cells under directed differentiation toward a chondrocytic 
phenotype.  Both studies have implications on our understanding of how chondrocytes 
may be manipulated (directed differentiation) in cell-based regenerative therapies for 
OA and the validity of current mechanistic models using established laboratory 
approaches.  An obvious future approach would be the application of stochastic 
modelling techniques to quantify the biological variability and uncertainty in single 
cell measurements [25, 26]; failing to consider this may influence the interpretation of 
in vitro experiments.    
   
Network medicine 
Interaction networks may be generated from the elements of a biological system; 
abstractions of these networks can facilitate an understanding of the architecture, 
activity, and key players in that system.  Much like a spider’s web a perturbation in 
one part of a network will be propagated throughout.  Network medicine postulates a 
‘disease module’ hypothesis, where disease-associated genes or proteins are likely 
share the same topological neighbourhood in a network.  Defining communities of 
network elements (genes, proteins) is a useful way to identify elements that have a 
close relationship, shared functionality, or disease association.  A systems biology 
approach to comprehending OA is founded on the hypothesis that OA is a multi-
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system disorder resulting from the dysfunction of a number of networks that, together, 
alter the homeostatic balance of the joint.  Therefore, comprehensive and multisystem 
approaches are necessary to understand the complexity of OA and direct the 
development of innovative treatment strategies. To date most studies pertaining to 
using a systems approach in OA research are principally based on interrogation of a 
single ‘omics survey in a single tissue at a single time point.  A reference set for 
transcriptomic and proteomic studies is provided in Table 1.  Genome-wide 
association studies in OA are reviewed elsewhere [27-29].     
 
Network-based systems orientated studies 
Network-based approaches make use of known or inferred functional and physical 
interactions between the elements of a system or can be developed from statistical 
associations (e.g. correlations between expression values) a priori giving a high-level 
understanding of the organisation of the system [18].  Data is often collected from 
disparate sources and organised into a coherent structure that can be interrogated by 
graph theory or logical (probabilistic) approaches [25].    Additionally, they can be 
applied in a flexible manner to multi-omics and clinical data, and across scales.  
Several studies have used network-based approaches to define communities of 
molecules that share the same neighbourhood within a network as molecules 
implicated in OA.  Work by Nacher, et al, [30] made use of the Google PageRank 
algorithm to define novel disease candidate proteins that share a network 
neighbourhood with known OA proteins.  These high-ranking proteins were derived 
from an interactome constructed from multiple proteomic studies of chondrocytes.  
The assumption is that membership by novel candidate proteins of an OA-associated 
sub-network means they are more likely to be subjected to the same perturbations.  
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The small, ubiquitin-related modifier SUMO4 was shown to interact with 15 OA-
associated proteins with the main interacting partners related to glycolysis and redox 
regulation.  Using existing protein-protein interaction data and an automated sub-
network searching tool (jActiveModules [31]) Loeser, et al, defined a sub-network 
associated with genes up-regulated during the initial 4 weeks after destabilisation of 
the medial meniscus (DMM) in a murine model, including heparin-binding EGF-like 
growth factor (HB-EGF) [32].  Olex and colleagues [33] developed this strategy 
further using time-course gene expression data from a whole mouse joint model of 
OA to define perturbed sub-networks.  ECM-receptor interaction and focal adhesion 
canonical pathways were enriched across all time-points.  This approach facilitated an 
understanding of the global phasic changes in expression of classic OA-associated 
genes following joint trauma.       
Protein-protein interactions represent compound data arising from many cell 
types and biological contexts so may not be indicative of the biological system under 
investigation and so generic networks without biological specificity may arise.  Soul, 
et al [34] developed an integrated tool (PhenomeExpress) to define context-specific 
sub-networks in an unbiased manner.   This method utilised prior knowledge of cross-
species phenotype-to-gene connections to establish sub-networks containing 
differentially expressed genes describing associations with a phenotypic correlation in 
the disease of interest.  The largest sub-network identified was annotated with immune 
function terms consistent with an understanding of pro-inflammatory changes in sub-
chondral bone in OA.  Further work by this group [35] using the PhenomeExpress 
approach in a small, paired RNA-seq analysis of OA cartilage versus normal sites 
defined several sub-networks associated with Wnt-signalling, apoptosis, matrix 
organisation, and mitotic cell cycle.  
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Other network approaches have included the use of Boolean dynamics to 
consider the coupled sequential reactions (signal propagation) between elements of a 
pathway to define a mechanistic network that was predictive of the response of primary 
chondrocytes to different ligands, including those associated with OA pathophysiology 
[36].  Our own work has included the use of weighted gene co-expression analysis 
(WGCNA) [37] to define sub-networks of highly connected genes (modules) that have 
strong associations with sub-groups of human osteoarthritic cartilage.  We 
demonstrated cross-species preservation of system development and immune-
associated modules between gene expression profiles from human OA and rodent 
models (unpublished data).  As these examples perhaps confirm, the frequency with 
which comparable key regulators and functional descriptors arise in these studies may 
be attributable to the data bias previously described.    
   
Mechanistic studies and dynamic models 
The limitation of many network approaches is that they require mapping of expression 
data onto pre-existing protein interactions and so rely heavily on prior knowledge of 
signalling and metabolic pathways.  Furthermore, statistical associations are made 
with respect to end-stage disease phenotypes, rather than having pre-osteoarthritis as 
the focus of investigations.  Critically, network approaches cannot capture 
spatiotemporal, dynamic changes in the system.  Generally, network approaches in 
OA have been useful in identifying novel targets and sub-networks, however, further 
mechanistic evaluation, perturbation, simulation, or validation of the proposed sub-
networks are performed infrequently.  Complex disease phenotypes change with time 
and are subject to biochemical and biophysical fluxes.  Often, the signals of interest 
may be spatially constrained, e.g. cell-matrix interface.  Network models cannot 
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capture this and so require to be coupled to dynamic models to provide a description 
of how a system progresses both in space and time.  Only a few studies have 
considered this for chondrocytes or with respect to OA.  Using observed 
immunohistochemical changes in cartilage from ageing mice and candidate proteins 
associated with cartilage destruction and ageing Hui, et al, developed an integrated 
computational model accounting for progressive collagen loss and increased MMP13 
production [38].  By modulating pathway elements the study demonstrated oxidative 
stress and the IL-1 pathway were integral to progressive loss of cartilage matrix.  
Notably, the model predicted differential temporal expression of MMP13 through the 
simulated inhibition of IL-1 or ALK1.  This approach is more useful than descriptive 
‘omics studies for developing a detailed, tissue-specific, mechanistic understanding 
and simulating temporal responses to perturbations facilitating rational hypothesis 
development for further testing.  Both network-based and molecular approaches 
provide useful insights into the pathophysiology of OA, but have not been used as 
part of a systems-biology continuum.  Kerkhofs, et al [39], developed a mathematical 
model to examine the switch from resting/proliferating chondrocytes to hypertrophy 
[40, 41].  The systems approach included a form of Markov chain model to predict the 
probability of particular factors pushing a chondrocyte towards a proliferative (Sox9) 
or hypertrophic (Runx2) phenotype.  There is currently a dearth of validated dynamic, 
mechanistic models and a critical need to link these ‘bottom up’ studies to the 
network models generated by ‘top-down’ approaches.    
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Constraint-based models of metabolism 
An understanding of the metabolic derangements associated with the joint tissues 
contributing to OA, and their molecular context, would be invaluable to defining 
pathogenic pathways especially given the evidence of whole-body metabolism effects 
on OA risk [42].  A number of contemporary studies have provided useful reference 
metabolomic and proteomic data from osteophytic cartilage [43], subchondral bone 
[44], and synovial fluid [45], or considered the role of metabolic pathways derived 
from transcriptomics data [33, 46]. However, our understanding of the homeostatic 
control of metabolic fluxes in cartilage, bone, and synovial fluid is limited.  
Constraint-based (CB) models facilitate a large-scale understanding of metabolic 
fluxes without the necessity for detailed kinetic information (see example from Hui, et 
al [38]), which is often lacking.  Information on the stoichiometry of all the metabolic 
reactions is considered within a pseudo-steady state that is optimised for a particular 
‘objective function’; methods include metabolic flux and flux-balance analysis (FBA).  
There are few examples in the literature relating to constraint-based approaches to 
modelling metabolic fluxes in joint tissues and no large-scale FBA simulations, 
including gene-knockout simulations, have been carried out for OA associated tissues.  
In Salinas, et al [47], the authors used metabolic flux analysis to determine the 
changes in central metabolism pathways in chondrosarcoma-derived SW1353 cells in 
response to mechanical loads.  Although this study makes a novel contribution to our 
understanding only limited metabolic pathways are considered.  Furthermore, it 
becomes difficult to attribute metabolic changes arising from transduced mechanical 
signals to pro-matrix synthesis pathways. The limitations of the FBA approach relates 
to the inability to incorporate dynamic information or regulatory elements.  This 
requires the integration of ‘omics data into generic genome-scale metabolic 
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reconstructions [48, 49] to generate cell- and tissue-specific models.   Generic 
metabolic reconstructions serve as templates for more specific contexts.  High quality 
genome-scale generic human metabolic models are freely available and have recently 
been revised [50].  Considerable resources (e.g. COBRA Toolbox 2.0, [51]) have 
been made available to generate context-driven tissue/cell-specific metabolic models. 
This has been successfully performed either in a draft or high-quality model form for 
many cells and tissues [49] but, musculoskeletal tissues are poorly represented 
(skeletal muscle [52], foetal cartilage [53]), if not absent from these analyses.   
Unlike constraint-based metabolic flux analyses of micro-organisms a 
metabolic understanding of OA requires the construction and coupling of metabolic 
networks for multiple tissues from the same organism.  Common interactions may be 
defined by metabolites that are secreted or consumed between tissues, but defining 
these elements, the post-transcriptional modifications that govern tissue-specific 
metabolic activity profiles [52],  and the extent to which this coupling occurs in vivo 
is a considerable challenge.  In the case of micro-organisms, or neoplastic tissues, the 
functional objective is growth.  In trying to develop a multi-scale model of the 
articular joint in the adult human the functional activities of each tissue are will be 
distinct from growth, but likely to have an optimisation or efficiency objective [48].  
Practical frameworks for the development of these context-driven models are 
available [49]; it should be a priority in osteoarthritis research to develop joint tissue-
/cell- specific metabolic models.  Overall, there is a necessity to make use of the 
available data to define cell-/tissue-specific metabolic models that incorporate 
molecular information from ‘omics studies.  Large-scale simulation and perturbation 
studies using CB analysis should be undertaken.  Gene knock-outs can by simulated 
in tissue-specific models to direct further molecular validation of regulatory 
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mechanisms [54].  Methods to infer missing or unidentified metabolites in untargeted 
metabolomic studies, incorporating network techniques, will facilitate a tissue-
specific understanding [55].    These studies, in due course, will provide the input to 
the development of coupled, multi-tissue whole joint metabolic models.  Such 
projects are on the scale of those undertaken for the liver, brain, and kidney or for 
particular diseases (e.g. diabetes); as such, they will require collaborative efforts.   
 
Image-based physiological models 
Physiological models derived from advanced imaging techniques (computed 
tomography (CT), micro-CT, magnetic resonance imaging (MRI), and in vitro 
techniques, e.g. quantitative microscopy) may be used to simulate musculoskeletal 
systems and are useful approaches to developing a systems understanding of OA.  The 
data is derived directly from the applicable study group, physiological conditions may 
be applied in a repeatable manner, and temporal changes may be simulated. 
Predictions of the material properties of the constituent tissues may be made that 
could not otherwise be easily measured experimentally; multiple tissues, or specific 
tissue elements, may be considered in their physiologically relevant setting.  The 
approach is non-destructive and tissue-failure conditions may be estimated in a non-
invasive manner.  The temporal impact of pathology or treatment can be simulated in 
the model.  Overall, these approaches are cheaper, faster, and knowledge-driven than 
in vivo models.  The integration of high-resolution geometry available from advanced 
imaging techniques and constraints defined by biomechanical data may be used to 
develop finite element simulations of the joint tissues.  Although these imaging 
techniques have been more widely applied to muscle and bone this modelling 
approach is uncommon for cartilage and sub-chondral bone in the context of OA 
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although some reports are found in the literature.  For example, using high-resolution 
micro-CT of the mouse tibia it has been possible to estimate the mechanical 
characteristics of the femoro-tibial joint DMM surgery using finite element analysis 
(FEA) [56].  The dynamic structural damage that occurs at the articular cartilage, 
which would otherwise be difficult to test, was explored in silico.  Mononen, et al, 
[57] also used finite element modelling to simulate cartilage degeneration using MRI 
data of knee joints from normal weight and obese OA patients.  Using a functional 
imaging approach to reveal bone metabolism Hirata and colleagues [58] correlated 
changes in 18F-fluoride PET (positive-emission tomography)  uptake with stress 
distributions in the subchondral bone of coxo-femoral joints from patients.  These few 
examples suggest that there is still considerable work required to link clinical or 
functional measurements with in silico models for a number of OA-associated tissues.  
There are efforts to develop standardised, open-source finite element joint models 
[59], but this requires not only to capture the variation in human anatomy, mechanics, 
and kinematics, but they are also required for model species where the majority of 
basic studies will be validated.    
 
Multiscale modelling 
The purpose of multiscale models is to develop early patient-orientated intervention 
packages based upon a realisation of trauma risk, the predicted performance of an 
intervention, and the prognostic capacity of biomarkers or clinical measurements as 
proxies for cell-level responses [3, 60].  As we have highlighted in the sections above, 
there are approaches to integrating high-throughput data into tissue-coupled, 
constraint-based metabolic models, and across scales for mechanical studies [61], but 
this is not yet a common approach in OA.  Additionally, there is no evidence of clear 
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‘omics integration approaches relevant to OA in the literature.  To make significant 
progress in our understanding of OA pathogenesis, metabolic and biomechanical 
models will have to be coupled across multiple temporal and spatial scales, Figure 3 
and Figure 4.  Biological systems already integrate all this information, however, for 
researchers this is a non-trivial concern with a large number of complex modelling 
and data integration techniques available [62, 63].  Ageing and sex manifests as 
anatomical and mechanical changes [64] that must also be integrated into multiscale 
models.  It is evident that there is still insufficient basic structural and molecular 
understanding of the elements of OA-associated tissues to fully realise multiscale 
approaches at this time.  One alternative strategy that offers a way to approach 
multiscale problems and simulate complex systems behaviour is agent-based 
modelling (Figure 4) [25]. The activity and interaction of autonomous ‘agents’ (e.g. 
cells), consisting of simple behavioural rules, may be formulated to simulate the 
collective behaviour of these agents.  As yet, this is not an approach that has been 
applied to the study of osteoarthritis associated cells and tissues, but has found utility 
in other complex conditions [65]. 
 
A systems biology case study: mechanotransduction in osteoarthritis 
Mechanotransduction is the transfer of biomechanical forces into intracellular 
chemical or electrical signals and many diseases are associated with dysregulation of 
this activity [66, 67].  OA may also be considered a disorder of mechanotransduction 
given that forces on the joint are integral to the health of the cartilage [68] and 
evidence that OA and aged chondrocytes have altered mechanical properties [69-71].  
Biomechanical signals are also multiscale responding to age and disease, Figure 3, 
with effects at a tissue level (differential loading across joint, load sharing across 
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particular tissues), within a tissue (differential compression on zonal regions of 
cartilage) and cell-associated (mechanotransduction through the pericellular matrix of 
the chondron) [60].  Critically, there is not a single mechanical signal that transduces 
into an electrical or chemical signal intracellularly and different forces require a level 
of integration (compression, osmolarity, fluid shear, hydrostatic pressures); the 
contribution of each still needs to be defined [72].  Given that mechanical signals 
have to be transduced through the extra- and peri-cellular matrix to allow 
chondrocytes to respond to their physical environment mechanotransduction 
mechanisms are potential therapeutic targets.  
Work by Guilak and colleagues, has considered numerous modelling 
strategies, including FEA, to deduce mechanical responses in chondrocytes and 
associated peri-cellular matrix, which helped define the complex mechanical 
environment consisting of changes in tension, fluid pressure/volume, shear, etc [73, 
74].  Using a mechanistic approach a Ca2+ responsive osmomechano-TRP channel 
TRPV4 was found to be critical to transduction of mechanical and osmotic signals 
[75] with enhanced anabolic gene expression and increased matrix production 
demonstrated using a chemical agonist [72].  Further work, using a cartilage-specific, 
inducible knock-out of Trpv4 revealed a reduction in age-associated OA at 12 months, 
but not in a DMM model [76].  This is in contrast to the severe OA phenotype 
observed in ageing mice with a global Trpv4 knockout.  Defining differential 
mechanotransduction pathways for age- and trauma-associated OA could establish 
therapeutic targets.  Modifications to a known small molecule TRPV4-antagonist has 
shown analgesic and anti-inflammatory properties that could have potential in a 
number of conditions including osteoarthritis [77]. This case-study demonstrates that 
a systems orientated approach (running in this case from ‘top down’) can reveal 
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regulatory targets by modelling the integration of mechanical signals to establishing 
common mechanotransduction mechanisms and unravelling age-associated 
contribution to biomechanical failures.  By integrating clinical level mechanical and 
kinematic data with an understanding of cell-level, molecular responses preventative 
and early therapeutic approaches may ultimately be employed in patient-specific 
programmes.  
 
Physiology-based models 
As discussed earlier there are limits to the application of in vitro models of OA tissue 
derangement.  Physiology–based models allow perturbations to be integrated into a 
physiological environment so it is relevant to the scope of this review.  Animal 
models of complex disease can facilitate a deeper understanding of the natural history 
of the pathology by providing controlled representations of subsets of human disease, 
however, there is no single standardised in vivo model and models that better 
represent the dynamics of human OA are required [78-80].  Animal models build in 
another level of complexity, not least of which are differing temporal dynamics.  
Often systems biologists will use genetically simple organisms (e.g. Caenorhabditis 
elegans) to reduce the complexity of the systems under investigation.  This has not 
been possible with OA given the particular complexity of the mammalian skeleton.  
However, recently some advances have been made in developing the zebrafish as a 
model of cartilage dysregulation [81, 82].   
Using developmental stages is often useful in systems orientated studies as 
they are conceptually simpler and easier to visualise.  Depending on the model, 
spatiotemporal changes in expression profiles can be followed and contribute 
parameters to dynamic in silico simulations.  Chondrogenesis, endochondral 
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ossification, and OA pathways share regulators [83] switching between proliferative 
and hypertrophic differentiation phenotypes is critical in these cases [84, 85]; 
mechanisms are employed to prevent or instigate this switch during development of 
articular cartilage, for example.  Unlike endochondral ossification, the core regulatory 
network in articular cartilage development has not been resolved.  It remains unclear 
how spatiotemporal patterns of gene expression in articular cartilage are associated 
with loss of function.  Some studies that develop mathematical models of 
endochondral ossification and the balance between proliferating and hypertrophic 
chondrocytes have been undertaken [86, 87], but further mechanistic studies of 
development pertinent to an understanding of OA pathogenesis should be undertaken.  
Spatiotemporal expression mapping and reference atlases has been used to understand 
the dynamics and localisation of key factors in developing tissues [88]; such an 
approach in joint tissues from model species would help span anatomical and 
molecular scales facilitating the development of cartilage expression networks and has 
been used in the zebrafish [82].  There is a clear need for integration of work and tools 
pioneered in the field of developmental biology to be extrapolated to OA systems 
biology.    
Applying systems approaches in the clinical setting 
We have highlighted the inherent complexity that researchers face in trying to answer 
the many unresolved questions in OA pathogenesis; this complexity it also 
demonstrable at the clinical level, not least given the multiple co-morbidities that may 
be present in clinical presentations of OA.  There are systems orientated approaches 
that may be applied to integrate mixed predictors (both qualitative and quantitative) of 
risk.  Decision trees are one form of machine-learning (ML) classification tools that 
may be applied to systems biology problems including clinical decision-making for 
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complex conditions [89].  The tree structure develops from the recursive branching at 
binary decision points that splits a clinical data set into two mutually exclusive 
subsets.  They are useful because they are intuitive (classification proceeds through a 
series of hierarchical logic questions) and are flexible in their application, being able 
to handle both real-value and categorical features (e.g. biomarker levels in blood and 
radiographic scores) and multiple classes [90] compared to some other forms of ML.  
Some examples of simple decision tree approaches have been published for clinical 
decision making in OA relating to imaging [91] and arthroplasty [92, 93], but there is 
no evidence in the literature of more complex clinical decision trees for the 
classification of early osteoarthritis risk using predictors from multiple sources (e.g. 
imaging and biomarkers, SNPs).  Further application of machine-learning approach, 
such as decision trees and random forests (ensembles of decision trees) are required to 
deal with the multi-scale predictors of OA risk that will emerge with systems-
orientated studies to aid clinical decision making.   
 
Applying systems approaches in the drug development pipeline 
Standard treatments in OA have broadly consisted of physical interventions and 
behavioural modifications (e.g. weight loss), pharmacological, and surgical 
interventions.  The limitations of traditional pharmacological approaches to the 
symptomatic treatment of OA arise from their equivocal efficacy and/or unacceptable 
side-effects.  A number of next-generation therapeutics are in clinical trial, though 
few have been developed to a point where regulatory approval has been granted [22].  
Exciting new approaches, such as the use of poly-micelle protected Runx1 mRNA 
[94], demonstrates that, in principle, articular cartilage is amenable to RNA-based 
therapeutics.  Given that small molecules with Runx1-mediated chondroprotective 
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properties, including kartogenin [95] and TD-198946 [96, 97], have been defined 
using high-throughput candidate molecule screens and not systems biology 
approaches, can systems orientated approaches solve the problem of defining novel 
therapeutic targets?  Systems orientated approaches augment, but do not replace 
reductionist strategies.  They should, however, make reality the objectives of 
personalised medicine by understanding that network derangements, which are 
unlikely to be the same between individuals, are the core of complex disease 
pathogenesis.  With respect to the indications for therapeutic use the lack of sensitive 
staging and phenotypic descriptors (OA phenome) means OA clinical trials will have 
a ‘one-size-fits-all’ approach; in demonstrating efficacy this may become problematic, 
requiring large and expensive trials.  Systems approaches can facilitate the integration 
of clinical and ‘omics data, stratify clinical sub-populations, and facilitate translation 
between animal and human through an understanding of shared network structure 
[98].  In isolation the relative contributions of biology, structure, and mechanics may 
not result in OA, but rather an understanding of the interplay, and common regulatory 
mechanisms, between these components of joint health is required [21].  It is likely 
that we need to consider therapeutic options that target multiple tissues to tackle OA, 
consequently, appropriate mechanistic modelling approaches to compare between cell 
types is required to establish therapeutic targets within signalling pathways that are 
relevant to both tissues [25]. This is exemplified by the emerging discipline of systems 
pharmacology.  Here traditional quantitative pharmacological approaches 
(pharmacodynamic/kinetic models) are combined with computational modelling of 
the regulatory networks of the cell [99].  This will become particularly relevant with 
the maturation of RNAi and CRISPR technology as therapeutic options.  We have 
already mentioned that in complex diseases it is unlikely that a single regulatory 
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target will suffice as a therapeutic option.  As an example, a standard 
pharmacodynamic approach may be based on a single biomarker of interest, whilst an 
understanding of the multiple interactions of the drug with other components of a 
network, applicable in systems pharmacology, will help determine its efficacy.   
 
Systems orientated objectives for OA diagnostics 
High-throughput screening has become possible with ‘omics technologies to define 
prognostic markers for OA (reviewed here [100]).  Without a clearer understanding of 
the biological mechanisms involved in the aetiopathogenesis of OA the search for 
reliable predictors or markers of phenotypic groups would be especially challenging 
[101].  Joint space narrowing is still the FDA-approved standard for clinical efficacy 
and many of the other outcomes are inferred. MRI provides moderate sensitivity and 
there are few biochemical tests that are prognostic or diagnostic [102, 103].  
Currently, efforts to validate and qualify new biomarkers are focussed on further 
imaging and biochemical tests (Osteoarthritis Biomarker Consortium).  It is notable 
that integrative and predictive modelling of multiscale data is not an objective for this 
programme.  Within other drug development pipelines, e.g. oncology, the co-
development of companion diagnostic tests is now either common or strongly 
recommended [104].  The lack of validated and specific biomarkers will retard 
advances in OA therapeutic development, as well as increase the cost of the 
associated clinical trials [105]; the potential benefit of OA therapeutics will only come 
from early identification of susceptible individuals and their appropriate stratification.  
This concurs with the work of Chu and others who maintained that the key to 
prevention and treatment is the capacity to define pre-osteoarthritis [21, 106].  
Systems approaches will encourage this type of approach to develop predictive 
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models with diagnostic and prognostic capacity.  An understanding of the interaction 
networks can be useful in defining similarities in phenotypes, classifying phenotypes, 
response to treatment, in addition to revealing potential targetable components of the 
cellular system [18].  For example, in work from our group (unpublished data) the 
Rho GTPase dissociation inhibitor Arhgdib was found to discriminate between 
healthy and diseased cartilage derived from the RAAK dataset [107].  Other machine 
learning tools have been used for discriminatory analysis of a combination of 
biochemical markers, including citrullinated protein expression, between individuals 
with musculoskeletal disorders including early OA [102].  As systems approaches bed 
down in OA research a key objective is to undertake discrimination analysis to 
establish genetic sub-populations.  For the part of the clinicians this requires accurate 
recording of phenotypic information, which is often lacking from public data 
repositories.     
 
Verification and validation in systems biology  
Systems biology requires considerable resources and high returns are expected.  
Critical appraisal of the capacity of systems biology to meet its aims in the context of 
OA research is required.  In systems approaches where many thousands of predictions 
are left unverified [108] attention to robust validation strategies is essential whilst 
reproducibility remains an unresolved issue in particular within the field of high-
throughput ‘omics.  Rationale methods to verify competing models must be in place 
[109], to quantify the uncertainty in the models, ensure evidence for their application, 
and assess the credibility of the predictive capacity of such models.  Some calls for 
model standardisation in systems biology have been made [110], however, transparent 
publication and model sharing, release and reuse of data and code, standardised peer-
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review processes and open-source resources will be integral to progress of OA 
systems orientated studies.  Early efforts should be made in the OA research 
community.   
 
Conclusions and directions for future research 
In the course of the review we describe a number of approaches used by colleagues to 
gain a systems understanding of basic biology and OA development, but the 
functional output and clinical impact – changing research and clinical practice, 
reliable diagnostics and disease-modifying therapeutics – arising from these studies is 
not apparent at this time.  The promise of systems approaches has been heralded for 
the last two decades as a source of new therapeutics and robust diagnostics [111].  It 
is clear that this has not been the case for OA.  The future success of systems 
orientated research in OA will rely on a number of points raised in this review.  
Firstly, concerted, community-based (clinicians and researchers) approaches are 
required, with the use of standardised models and multi-disciplinary teams, advances 
should be possible.  The comprehensive collection of data, integration, discriminatory 
analysis, and predictive models should be a primary objective.  What is becoming 
clear is that we do not require more bioinformatics or ‘dead’/static descriptions rather 
dynamic (‘living’) mechanistic models and robust validation frameworks for models 
and we offer examples of approaches that, having shown utility in other disciplines, 
may have application in OA research (Figure 4).  We stress that modelling itself is 
not an end-point for osteoarthritis research, rather it can facilitate the design of more 
direct and relevant experimental approaches.  More subtle descriptors and 
development of the OA phenome, in addition to a refocusing of research strategies 
towards pre-osteoarthritis, is critical.  Clinical measurements need to be coupled to 
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predictive models of cellular response to help direct rational intervention 
programmes for patients at high risk.  The advent of mobile health and wearable 
technologies, and an understanding of social network trends on health, will facilitate 
collection of clinical and mechanical meta-data to incorporate into patient-specific 
models.  Systems pharmacology approaches recognise that single therapeutic 
interventions for complex diseases are unlikely to be efficacious and insufficiently 
tailored to patients.  RNA therapeutics will emerge as an important tool in network 
medicine and have the potential to promote personalised interventions in 
osteoarthritis.  Ultimately, there is still much that is unclear about the mechanisms 
regulating the homeostatic system that still requires resolution before relevant 
multiscale models may be employed.    
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Figure Legends 
 
Figure 1: The iterative systems biology approach to defining novel diagnostic and 
therapeutic targets.  Schematic demonstrates a prototypical, multi-stage, systems 
orientated approach to develop novel diagnostic and therapeutic solutions to a 
complex disease problem such as osteoarthritis.  Not all options may be applicable in 
every study.  Omics surveys are depicted as intersecting ‘snap-shots’ of the biological 
hierarchy. Recursive profiling of the biological hierarchy is relevant in systems-
orientated approaches as it may reveal: a) patterns of activity and isolated structures 
are repeated at different levels; b) information at one hierarchical level may not 
represent activity at another; c) multi-directional causality, i.e. information passes 
both within and between levels in the hierarchy, and d) non-locality of function; i.e. 
the functional activity may occur distant to other system elements (e.g. synapses in a 
neuron, actin filaments at the leading edge of a cell).  The integration of these 
elements is critical to the development of mechanistic models; this may include 
defining scales by which to couple levels or use approaches that span scales (e.g. 
phenotype and gene expression).  The exposome defines an individual’s cumulative 
risk factors over their life (e.g. obesity, joint trauma).  Validation at the molecular 
level may give insights into regulatory principles to produce initial in silico 
simulations.  Testing the simulation, perturbing the system, and subsequent re-
profiling are further elements of the cycle.  The co-development of OA diagnostics 
and therapeutics is consideration within this process.  Given the considerable time and 
resources that are required to sustain this continuum suggests that community-
orientated approaches using standardised methodologies are essential.  Subsequently, 
patient feedback, adverse events, data from mobile health technologies, can be 
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incorporated into iterative rounds of improvement. The review demonstrates that in 
the last decade studies have only considered elements of this continuum, e.g. ‘omics 
surveys.  In general, studies are incomparable limiting that capacity to integrate.  
Figure developed from concepts introduced in [112, 113].  
 
Figure 2: Publication trends associated with the following query terms: ‘rheumatoid 
arthritis’ (ra), ‘osteoarthritis’ (oa), ‘systems biology’ (sb), or combinations of these 
terms (sbOA and sbRA) expressed as a percentage of the total number of publications 
(https://www.ncbi.nlm.nih.gov/pubmed) per year (2000-2014).  Trend lines for sbOA 
and sbRA have been ‘jittered’ to avoid over-plotting. Data for 2015/16 are incomplete 
and are not included.  Publications associated with OA have grown slowly with 
respect to RA; in contrast systems biology publications have shown a rapid increase 
in the decade following the publication of the Human Genome (2001) to represent 
~0.9% of publications in 2014.  Publications referencing either OA or RA and 
systems biology still account for a very small contribution to the total number of 
annual publications (0.001%).   
 
Figure 3: Multiscale complexity in developing systems models in osteoarthritis.   
a: Selecting and defining the appropriate sub-system for analysis is critical in a 
systems-orientated approach to complex diseases such as osteoarthritis.  Osteoarthritis 
presents multiscale, -system, and –physical problems.  Approaches may be considered 
‘top-down’ or ‘bottom-up’, though in practice this is not a sequential process with 
many studies adopting a ‘middle-out’ approach.  b: Coupling scales and integrating 
data across levels of the biological hierarchical is non-facile when attempting to 
derive useful prognostic, predictive or therapeutic outputs.  Osteoarthritis is presented 
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as a series of spatiotemporal problems.  For examples, time ranges from microsecond 
interactions in metabolic reactions to the course of human longevity, collagen 
turnover, and the requirement for a functional joint.  Spatially, anatomy, load sharing, 
propagation of mechanical signals, and localised responses at interfaces show 
considerable breadth. c: Network scales range from gene networks to social networks.  
The component of a network that is being considered is important, whether this is a 
simple interaction, a regulatory motif, or multiple sub-networks.    Additional 
complexity arises from a diverse phenome and inciting factors, stochasticity in gene 
expression, and non-local events. The use of animal models adds a layer of 
complexity to this problem and appropriate regard must be given to the spatial and 
temporal differences in these models.  Figure developed from concepts described in 
[3, 21, 60, 62].   
 
Figure 4: Future strategies for systems orientated studies in osteoarthritis – a: 
Coupling constraint-based, tissue-specific metabolic models requires the identification 
of metabolites that are shared across systems [48], e.g. sub-chondral bone and 
cartilage; simulation of single or multiple gene knock-outs [54] has also yet to be 
explored  b: Most analysis of cellular behaviour occurs at the population level and 
considers average responses.  More finely-grained appreciation of cellular behaviour, 
such as spatially-restricted signalling, requires stochastic modelling at a single-cell (or 
sub-cellular) level [26]; c: Most network models are static and have not been 
validated.  Dynamic models, using a series of ordinary differential equations, may be 
used to simulate a hypothetical regulatory mechanism (e.g. positive feedback), which 
may then inform in vitro validation studies; d: Agent-based modelling is a ‘bottom-
up’ approach that uses the activity and interactions of autonomous ‘agents’ (e.g. cells) 
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to simulate and predict the observed complex behaviour.  In this schematic the 
interaction space and potential states are depicted by a chess board where agents are 
represented by chess pieces; each has rational constraints to its behaviour.  Decision-
making heuristics and learning processes may be applied to simulate the complex 
behaviour of the system.  Such approaches have been frequently applied to multi-
scale problems [65] and may be applicable to modelling the complex behaviour 
within, and between, tissues [25].  e: Highly-detailed geometric information derived 
from advanced-imaging techniques and material properties can be used in finite-
element models of multiple musculoskeletal tissues [61].   
 
Table 1:  Example studies using systems biology approaches in OA relevant samples 
applicable to osteoarthritis research. 
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Figure 4 
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Question Sample     
Type Origin Species Goal Principle 
Platform(s) 
Reference 
Descriptive Tissue Cartilage Human OA; intact and 
damaged 
transcriptome 
RNASeq Dunn 2016 
[41] 
Descriptive Tissue Cartilage Human OA secretome Mass 
spectrometry 
proteomics, 
relative 
quantification 
Lourido 
2014 [91] 
Descriptive Tissue Cartilage Human  OA  secretome Mass 
spectrometry 
proteomics, 
absolute 
quantification 
Peffers 2013 
[92] 
Descriptive Cells Chondrocytes Equine Ageing 
transcriptome 
RNASeq Peffers 2014 
[93] 
Descriptive Cells Chondrocytes Human OA post 
transcriptome 
Microarray Tew 2014 
[94] 
Descriptive Cells Chondrocytes Human OA methylome Methylation 
arrays 
Rushton 
2014 [95] 
Descriptive Cells Chondrocytes Human OA  genetic 
loci 
GWAS Evangelou 
2014 [96] 
Descriptive Tissue Cruciate 
ligament 
Human Sex-related 
proteome 
Mass 
spectrometry 
proteomics, 
relative 
quantification 
Little 2014 
[97] 
Descriptive Fluid Synovial fluid Horse OA Mass 
spectrometry 
proteomics, 
relative 
quantification 
Peffers 2015 
[98] 
Descriptive Fluid Synovial fluid Human OA 
metabolome 
NMR 
metabolomics 
Zhang 2014 
[99] 
Descriptive Tissue Subchondral 
bone 
Rat OA 
transcriptome 
Microarray Zhang 2012 
[100] 
Descriptive Organ Joint Mouse Age and OA 
transcriptome 
Microarray Loeser 2012 
[101] 
Integrative Cells Cartilage, 
tendon 
Rat Transcriptomic 
changes in 
culture  
Microarray Mueller 
2016 [34] 
Integrative Cells Bone-marrow 
derived MSCs 
Human Transcriptome 
and methylome 
ageing 
RNASeq, 
methylation 
array 
Peffers 2016 
[102] 
Integrative Tissue Synovial Human OA 
Transcriptome 
and proteome 
Microarray Lorenz 2003 
[103] 
Integrative Organ Joint Mouse OA time course Microarray Olex 2014 
[39] 
Integrative Cells Chondrocytes Human OA Microarray and 
protein 
microarray 
Illiopoulos 
2008 [104] 
Pertubation/
model testing 
Cells Chondrocytes Human OA microRNA miRNASeq Crowe 2016 
[105] 
Computer 
model-led 
Organ Joint Mouse Age Computer 
modelling 
Hui 2014 
[44] 
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Computer 
model led 
Cells  Chondrocytes Human Cartilage 
breakdown 
Computer 
modelling 
Proctor 2014 
[106] 
Computer 
model led 
Cells  Chondrocytes Human  Cytokine 
response 
Computer 
modelling and 
proteomics 
Melas 2014 
[42] 
Computer 
model led 
Cells Periosteal 
derived stem 
cells 
Human Chondrocyte 
hypertrophy 
Computer 
modelling and 
gene 
expression 
analysis 
Kerkhofs 
2016 [46] 
Computer 
model led 
Organ Knee joint Human Assessing 
surgical 
treatments for 
osteoarthritis 
Computer 
modelling, 
MRI of knee 
joints 
Mootanah 
2014 [60] 
Computer 
model led  
Organ Brain 
(endocannabinoi
d system) 
Human Pain response 
in osteoarthritis  
Computer 
modelling  
Benson 2014 
[107] 
Computer 
model led 
Organ Knee joint Human  Stresses in 
response to 
cartilage 
overloading 
Computer 
modelling  
Mononen 
2016 [61] 
 
Table 1 
   
